Fig. 1
From: Local delivery of accutox® synergises with immune-checkpoint inhibitors at disrupting tumor growth
AccuTOX® triggers immunogenic cell death. A Schematic diagram outlining the strategy used for the generation of the Accum® variants. B A predicted 3D model depicting the structure of the AccuTOX®. C A killing dose–response curve conducted on the EL4 lymphoma cell line to identify the IC50 dose. D Representative flow-cytometry analysis assessing Annexin-V+ using three different cancer cell lines (EL4, B16 and E0771) following an overnight in vitro treatment with AccuTOX® (33 μM). Control cells are shown by gray histograms. E Assessment of ATP secretion levels overtime in response to AccuTOX® treatment (33 μM). F Flow-cytometry analysis of Calreticulin+ cells in response to AccuTOX® treatment (33 μM). G The mean fluorescent intensity (MFI) of the Calreticulin signal shown in panel F. For panels G, n = 6/group with ***P < 0.001. All experiments shown in this panel were repeated 3 times